ArticlePloS one2026
Life expectancy and mortality of people with and without diabetes in Aotearoa | New Zealand: A national cohort study.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetes mellitus (DM) is a significant driver of excess morbidity and premature mortality, though few contemporary or locally-derived data quantify this impact on New Zealanders, particularly Māori and Pacific Peoples. This prospective, national population study examines the life expectancy (LE) for New Zealanders with and without DM, and characterises mortality rates.
methodsData from 01/01/2015 to 31/12/2019 housed in the Integrated Data Infrastructure, including the Virtual Diabetes Registry and Health New Zealand Mortality Collection, were linked. Estimated remaining LE years were calculated using abridged period life tables using the Chiang method for those with type 1 diabetes (T1D), type 2 diabetes (T2D), and without DM. Sub-group analysis by ethnicity was completed. Five-year cause-specific mortality rates per 100,000 people were compared by DM group.
findingsT1D and T2D prevalence was 0.4% and 5.5% in the overall sample (n = 4,505,478). Considerable ethnic differences in LE were evident, for example a 13-, 17.1-, and 24.5-year loss in remaining LE years was seen in men aged 0-19 years with T1D in the overall, Māori, and Pacific Peoples groups respectively compared to those without DM. An age-dependent reduction in remaining life expectancy years was also evident; for example an 8.6 (8.5-8.7) year reduction seen in females with DM aged 0-4, and 4.0 (4.0-4.1) year reduction for women with DM aged 65-69. Those with DM had higher cause-specific death rates.
interpretationDM is associated with age-dependent reductions in LE across the entire lifespan, with disproportionately higher LE loss seen in Māori and Pacific Peoples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.